Polypharmacy in nursing home in Europe: results from the SHELTER study.

BACKGROUND This study assesses prevalence and patients characteristics related to polypharmacy in a sample of nursing home residents. METHODS We conducted a cross-sectional analysis on 4,023 nursing home residents participating to the Services and Health for Elderly in Long TERm care (SHELTER) project, a study collecting information on residents admitted to 57 nursing home in 8 countries. Data were collected using the interRAI instrument for long-term care facilities. Polypharmacy status was categorized in 3 groups: non-polypharmacy (0-4 drugs), polypharmacy (5-9 drugs) and excessive polypharmacy (≥ 10 drugs). RESULTS Polypharmacy was observed in 2,000 (49.7%) residents and excessive polypharmacy in 979 (24.3%) residents. As compared with non-polypharmacy, excessive polypharmacy was directly associated not only with presence of chronic diseases but also with depression (odds ratio [OR] 1.81; 95% confidence interval [CI] 1.38-2.37), pain (OR 2.31; 95% CI 1.80-2.97), dyspnoea (OR 2.29; 95% CI 1.61-3.27), and gastrointestinal symptoms (OR 1.73; 95% CI 1.35-2.21). An inverse association with excessive polypharmacy was shown for age (OR for 10 years increment 0.85; 95% CI 0.74-0.96), activities of daily living disability (OR for assistance required vs independent 0.90; 95% CI 0.64-1.26; OR for dependent vs independent 0.59; 95% CI 0.40-0.86), and cognitive impairment (OR for mild or moderate vs intact 0.64; 95% CI 0.47-0.88; OR for severe vs intact 0.39; 95% CI 0.26-0.57). CONCLUSIONS Polypharmacy and excessive polypharmacy are common among nursing home residents in Europe. Determinants of polypharmacy status include not only comorbidity but also specific symptoms, age, functional, and cognitive status.

[1]  P. Rochon,et al.  Exploring variation in rates of polypharmacy across long term care homes. , 2012, Journal of the American Medical Directors Association.

[2]  R. Lindley Drug trials for older people. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.

[3]  Harriet Finne-Soveri,et al.  Assessment of nursing home residents in Europe: the Services and Health for Elderly in Long TERm care (SHELTER) study , 2012, BMC Health Services Research.

[4]  F. Lattanzio,et al.  Predictors of hospitalization in Italian nursing home residents: the U.L.I.S.S.E. project. , 2012, Journal of the American Medical Directors Association.

[5]  G. Onder,et al.  The risk of adverse drug reactions in older patients: beyond drug metabolism. , 2011, Current drug metabolism.

[6]  D. Abernethy,et al.  Geriatric drug evaluation: where are we now and where should we be in the future? , 2011, Archives of internal medicine.

[7]  R. Sulkava,et al.  Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three‐year period in an elderly population , 2011, Pharmacoepidemiology and drug safety.

[8]  M. Tinetti,et al.  Primary care clinicians' experiences with treatment decision making for older persons with multiple conditions. , 2010, Archives of internal medicine.

[9]  Need for redesigning pharmacologic research in older individuals. A position statement of the Geriatric Working Group of the Agenzia Italiana del Farmaco (AIFA). , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.

[10]  Göran Petersson,et al.  Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008 , 2010, BMC clinical pharmacology.

[11]  Graziano Onder,et al.  Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score. , 2010, Archives of internal medicine.

[12]  K. Yaffe,et al.  Potentially inappropriate medication use in older adults with mild cognitive impairment. , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.

[13]  D. Woodwell,et al.  Polypharmacy in nursing home residents in the United States: results of the 2004 National Nursing Home Survey. , 2010, The American journal of geriatric pharmacotherapy.

[14]  R. Sulkava,et al.  Polypharmacy Status as an Indicator of Mortality in an Elderly Population , 2009, Drugs & aging.

[15]  G. Onder,et al.  Development of CRIteria to Assess Appropriate Medication Use among Elderly Complex Patients (CRIME) Project , 2009, Drugs & aging.

[16]  J. Guralnik,et al.  Basic ADL disability and functional limitation rates among older AMERICANS from 2000-2005: the end of the decline? , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.

[17]  Yazan F. Roumani,et al.  Number and dosage of central nervous system medications on recurrent falls in community elders: the Health, Aging and Body Composition study. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.

[18]  Caroline Blaum,et al.  The Co‐Occurrence of Chronic Diseases and Geriatric Syndromes: The Health and Retirement Study , 2009, Journal of the American Geriatrics Society.

[19]  H. Holmes Rational Prescribing for Patients With a Reduced Life Expectancy , 2009, Clinical pharmacology and therapeutics.

[20]  Mats Thorslund,et al.  The Influence of Educational Level on Polypharmacy and Inappropriate Drug Use: A Register‐Based Study of More Than 600,000 Older People , 2009, Journal of the American Geriatrics Society.

[21]  S. Hilmer,et al.  The Effects of Polypharmacy in Older Adults , 2009, Clinical pharmacology and therapeutics.

[22]  Graziano Onder,et al.  Multidimensional Geriatric Assessment: Back to the Future Second and Third Generation Assessment Instruments: The Birth of Standardization in Geriatric Care , 2008 .

[23]  Emily R. Hajjar,et al.  Polypharmacy in elderly patients. , 2007, The American journal of geriatric pharmacotherapy.

[24]  T. Søeborg,et al.  Risk assessment of topically applied products. , 2007, Toxicology.

[25]  N. van der Velde,et al.  Syncope and falls due to timolol eye drops , 2006, BMJ : British Medical Journal.

[26]  Julia K. Nguyen,et al.  Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. , 2006, The American journal of geriatric pharmacotherapy.

[27]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[28]  B. Sproule,et al.  Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits , 2005, BMJ : British Medical Journal.

[29]  Vincent Mor,et al.  A Comprehensive Clinical Assessment Tool to Inform Policy and Practice: Applications of the Minimum Data Set , 2004, Medical care.

[30]  J. Hanley,et al.  Statistical analysis of correlated data using generalized estimating equations: an orientation. , 2003, American journal of epidemiology.

[31]  M. Cesari,et al.  Adverse drug reactions and cognitive function among hospitalized older adults , 2002, European Journal of Clinical Pharmacology.

[32]  A. Mitchell,et al.  Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. , 2002, JAMA.

[33]  G. Onder,et al.  Minimum Data Set for Home Care: A Valid Instrument to Assess Frail Older People Living in the Community , 2000, Medical care.

[34]  D. Brauner,et al.  Treating nondementia illnesses in patients with dementia. , 2000, JAMA.

[35]  J N Morris,et al.  Development of a minimum data set-based depression rating scale for use in nursing homes. , 2000, Age and ageing.

[36]  B E Fries,et al.  Scaling ADLs within the MDS. , 1999, The journals of gerontology. Series A, Biological sciences and medical sciences.

[37]  M. Pahor,et al.  A brief training program on resident assessment instrument improves motivation of nursing home staff. , 1999, The journal of nutrition, health & aging.

[38]  H. Brodaty,et al.  ALZHEIMER'S DISEASE INTERNATIONAL , 1997, International journal of geriatric psychiatry.

[39]  D. Mehr,et al.  MDS Cognitive Performance Scale. , 1994, Journal of gerontology.